Publications

Authors:

Gargiulo, L.; Ibba, L.; Malagoli, P.; Amoruso, F.; Balato, A.; Bardazzi, F.; Burlando, M.; Carrera, C. G.; Dapavo, P.; Dini, V.; Gaiani, F. M.; Girolomoni, G.; Guarneri, C.; Lasagni, C.; Loconsole, F.; Marzano, A. V.; Maurelli, M.; Megna, M.; Travaglini, M.; Costanzo, A.; Narcisi, A.

Title:

Long-term effectiveness and tolerability of apremilast in patients with moderate-to- severe plaque psoriasis: A 5-year multicentre retrospective study—IL PSO (Italian landscape psoriasis)

Year:

2024

Type of item:

Articolo in Rivista

Tipologia ANVUR:

Articolo su rivista

Language:

Inglese

Referee:

No

Name of journal:

Journal of the European Academy of Dermatology and Venereology

ISSN of journal:

0926-9959

Page numbers:

946-949

Keyword:

Long-term effectiveness and tolerability of apremilast in patients with moderate-to- severe plaque psoriasis

Short description of contents:

Apremilast is an oral inhibitor of phosphodiesterase (PDE)-4 that has been approved for the treatment of patients with moderate-to- severe plaque psoriasis who have contraindications or inadequate response to conventional systemic treatments. 1,2 It is also indicated for the management of adults with active psoriatic arthritis (PsA) who have failed or are intolerant to other disease-modifying antirheumatic drugs (DMARDs).1,2 In Italy, apremilast is reimbursed for patients with moderate-to- severe plaque psoriasis in case of inadequate response/intolerance to systemic treatments and those with contraindications to biological drugs.3 Despite the wide use of apremilast for the treatment of plaque psoriasis, long-term real-world experiences are still limited.4,5

Product ID:

142095

Handle IRIS:

11562/1144247

Last Modified:

October 31, 2024

Bibliographic citation:

Gargiulo, L.; Ibba, L.; Malagoli, P.; Amoruso, F.; Balato, A.; Bardazzi, F.; Burlando, M.; Carrera, C. G.; Dapavo, P.; Dini, V.; Gaiani, F. M.; Girolomoni, G.; Guarneri, C.; Lasagni, C.; Loconsole, F.; Marzano, A. V.; Maurelli, M.; Megna, M.; Travaglini, M.; Costanzo, A.; Narcisi, A., Long-term effectiveness and tolerability of apremilast in patients with moderate-to- severe plaque psoriasis: A 5-year multicentre retrospective study—IL PSO (Italian landscape psoriasis) «Journal of the European Academy of Dermatology and Venereology» , 2024 , pp. 946-949

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo